Traverse Biotech develops innovative products in partnership from the pre-clinical stage through clinical proof-of-concept, driving significant value for shareholders and maximizing patient benefit. Company identify cutting-edge immunology products from clinically validated platforms, sourced from international biotech and pharma companies. Firm then develop these products in a novel risk-sharing model with our partners, bringing game-changing medicines to patients sooner. Traverse Biotech's operational strategy is based on secure partnerships with inventing companies allowing us to leverage technical capabilities, manufacturing capacity, and regulatory information from our Partners. This frees us to rapidly reach value-creating milestones, launching our products sooner to the patient.
